ARTICLE | Company News
Harbour BioMed in antibody deals with BeiGene, ImmunoChina
January 9, 2018 12:44 AM UTC
Harbour BioMed (Shanghai, China) announced a pair of antibody-related deals with BeiGene Ltd. (NASDAQ:BGNE) and ImmunoChina Pharmaceuticals Co. Ltd.
Harbour granted cancer company BeiGene a license to access its H2L2 transgenic mouse platform for use in multiple programs over a multi-year period. Harbour's H2L2 mice generate human mAbs with both heavy and light chains. Terms of the deal, which was announced on Sunday, were not disclosed...